Lake Country Advisors

AUGUST 8, 2024

Accurate and appropriate valuation is one of the pillars of maximizing the profits from a business sale. However, company valuation isn’t as simple as slapping a price on your business. It’s a delicate balancing act, as inaccurate valuations have polarizing consequences.

Valuation 97

Valuation Discounted Cash Flow S&P DCF Analysis 97

Software Equity Group

MAY 7, 2024

2023 saw a myriad of factors impact SaaS M&A multiples, including economic developments, technological advancements, and a public market rebound. But what are the key influences shaping valuation multiples in today’s M&A deals? The most active verticals in 2023 were Healthcare, Financial Services, and Real Estate.

M&A 52

M&A Valuation Economics Business 52

Software Equity Group

MAY 8, 2024

2023 saw a myriad of factors impact SaaS M&A multiples, including economic developments, technological advancements, and a public market rebound. But what are the key influences shaping valuation multiples in today’s M&A deals? The most active verticals in 2023 were Healthcare, Financial Services, and Real Estate.

M&A 52

M&A Valuation Economics Business 52

Software Equity Group

MARCH 13, 2023

In terms of the target market, the top five SaaS verticals were led by Healthcare, as more and more companies in the healthcare sector turn to SaaS solutions to improve patient care and manage costs. Strategic buyers are publicly traded or privately owned software companies. In 2022, verticals made up 42%, a slight increase.

M&A 52

M&A Private Equity Equities S&P 52

Cooley M&A

OCTOBER 29, 2020

Given that a SPAC is an alternative means to going public, a significant portion of the webinar was dedicated to discussing some of the key differences—and similarities—between a SPAC and a traditional IPO. Valuation Certainty. Competition / Variation. Another feature of SPAC 3.0 is the competition among SPACs for potential targets.

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years. In June, GlaxoSmithKline announced its plans to spin off its consumer healthcare business to focus on its pharmaceutical and vaccine businesses.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40